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Abstract
Objectives—To characterize psychotropic medication use before and after traumatic brain injury 
(TBI) hospitalization among older adults. A secondary objective is to determine how receipt of 




Participants—Medicare beneficiaries age ≥65 hospitalized with TBI 2006-2010 with continuous 
drug coverage for 12 months before and after TBI (n=60,276).
Measurements—We obtained monthly psychotropic medication use by drug class and specific 
drugs from Medicare Part D drug event files. International Classification of Disease, 9th Edition 
CM, codes were used to define anxiety (300.0x) and PTSD (309.81).
Results—Average monthly prevalence of psychotropic medication use among all patients 
hospitalized for TBI was 44.8%; antidepressants comprised 73%. Prevalence of psychotropic 
medication use increased from 2006-2010. Following TBI, psychotropic medication use increased 
slightly (odds ratio (OR) 1.05; 95% confidence interval (CI) 1.03, 1.06.) Tricyclic antidepressant 
use decreased post-TBI (OR 0.76; 95% CI 0.73, 0.79) while use of the sedating antidepressants 
mirtazapine (OR 1.31; 95% CI 1.25, 1.37) and trazadone (OR 1.11; 95% CI 1.06, 1.17) increased. 
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Antipsychotic (OR 1.15; 95% CI 1.12, 1.19) use also increased post-TBI. Beneficiaries newly 
diagnosed with anxiety (OR 0.42; 95% CI 0.36, 0.48) and/or PTSD (OR 0.39; 95% CI 0.18, 0.84) 
post-TBI were less likely to receive indicated pharmacologic treatment.
Conclusions—Older adults hospitalized with TBI have a high prevalence of psychotropic 
medication use yet are less likely to receive indicated pharmacological treatment for newly 
diagnosed anxiety and PTSD following TBI.
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Traumatic Brain Injury; Psychotropic Medications; Older Adults; Neuropsychiatric disorders
Introduction
Traumatic brain injury (TBI) causes significant morbidity among older adults, resulting in 
over 142,000 emergency department visits and 81,500 hospitalizations annually in the 
United States.1 Further, rates of TBI among older adults are increasing.1,2 Older adults have 
the highest rates of hospitalization and mortality following TBI and are more likely to 
experience poor cognitive and functional outcomes, nursing home placement, and mortality 
compared to younger adults with similar injury severity.1,3-6
Individuals with TBI are at increased risk of neuropsychiatric disorders due to 1) trauma to 
brain regions involved in emotional regulation and behavioral control, and 2) longer-term 
cognitive and physical disability from the TBI resulting in loss of employment, previously 
enjoyed activities, family support, and social contacts.7-10 Although there is good evidence 
of the increased risk of neuropsychiatric disorders following TBI, there is insufficient high-
level evidence supporting the use of any pharmacologic treatments for neuropsychiatric 
disorders following TBI.10,11 Brain injury increases the risk of adverse events such as 
seizures and stroke, raising concerns that treatments for neuropsychiatric disorders may not 
have the same safety or efficacy in individuals with TBI.11-15 Physicians currently rely on 
evidence from a few small clinical trials and treatment of neuropsychiatric disturbances in 
the general population to guide treatment decisions for individuals with TBI. 8,11,12,16-20
Preliminary to the conduct of comparative safety analyses, a thorough examination of 
current use of psychotropic medications among individuals with TBI is warranted. Hence, 
the objective of this study is to characterize psychotropic medication use before and after 
TBI among older adults, a vulnerable population for whom there is little data on treatment of 
TBI neuropsychiatric disorders. As a secondary objective, we examine whether receipt of 
indicated pharmacologic treatment for anxiety and post-traumatic stress disorder (PTSD) is 
impacted by TBI.
Methods
We conducted a retrospective analysis of Medicare administrative claims data obtained from 
the Centers for Medicare & Medicaid Services (CMS) Chronic Condition Data Warehouse 
(CCW). In the United States, Medicare provides health insurance to individuals aged 65 and 
older and younger individuals with disabling conditions. Medicare consists of three Parts: A 
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(hospital), B (medical), and D (outpatient prescription medications). Beneficiaries can also 
enroll in Part C, in which a commercial insurer provides benefits. All elderly Medicare 
beneficiaries hospitalized with TBI during 2006-2010 were eligible. Inclusion criteria were 
age ≥65 at TBI, first TBI, and survival to hospital discharge. We defined TBI by searching 
for International Classification of Disease, 9th Revision Clinical Modification (ICD-9-CM) 
codes 800.xx, 801.xx, 803.xx, 804.xx, 850.xx- 854.1x, 950.1-950.3, 959.01) in any position 
on an inpatient claim. These ICD-9-CM codes represent the Centers for Disease Control and 
Prevention's (CDC) case definition for TBI, which previously has been reported to have a 
sensitivity of 89% to detect severe TBI and a positive predictive value of 93% to correctly 
identify TBI-related hospitalizations.21,22
Psychotropic Medications
We searched Medicare Part D prescription drug event files for evidence of psychotropic 
medication use. We created 30-day periods pre- and post-TBI hospitalization and defined 
medication use as 1) a filled prescription for any psychotropic medication; or 2) a proportion 
of days covered (number of daily doses in the prescription/number of days in the month) for 
any psychotropic medication >0. We defined five classes of psychotropic medications as: 
antidepressants, antipsychotics, mood stabilizers and anti-seizure medications, other 
anxiolytics (e.g. buspirone, hydrozyzine), and miscellaneous psychotropics (e.g. zolpidem, 
zaleplon). Appendix 1 contains a complete list of drug names, classes to which they were 
assigned, and indicated use in treatment of anxiety of PTSD. To ensure adequate time to 
capture patterns of medication use as well as comorbidities and diagnosis of 
neuropsychiatric disturbances, we required twelve months continuous Medicare Parts A, B, 
and D with no Part C (Medicare Advantage (HMO)) coverage both pre- and post-TBI 
hospitalization (twenty-four months total follow-up). Medications used during the 
hospitalization episode and during a skilled nursing facility (SNF) stay of <100 days are not 
consistently present in the Part D drug event file.
Anxiety and PTSD
Anxiety disorder (henceforth called anxiety) was defined as the presence of ICD-9-CM 
codes 300.0x on any inpatient or outpatient claim during the study period and PTSD as 
ICD-9-CM code 309.81. The first date of diagnosis occurring pre- and post-TBI was 
recorded and used to identify individuals with pre- or post-TBI disorders. We also created a 
variable indicating a new diagnosis post-TBI for those who did not have a previous anxiety 
or PTSD diagnosis.
Covariates
Demographic and enrollment characteristics were obtained from the CCW enrollment file 
and baseline comorbidities at TBI hospitalization were determined using CMS's CCW 
flagged comorbid conditions.23 These 27 chronic conditions are identified based on the 
presence of ICD-9 codes on inpatient, skilled nursing, home health, or outpatient claims 
using algorithms defined by CMS. The date of first diagnosis is listed for each flagged 
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condition. We used these to create time-varying comorbidity diagnoses throughout the study 
period.
Diagnosis and treatment of depressive disorder (depression) could strongly influence receipt 
of treatment for anxiety or PTSD, especially since medications used to treat these conditions 
often overlap. Therefore, we created indicator variables for pre- and post-TBI depression 
diagnoses, defined as the presence of ICD-9-CM codes 296.2, 296.3, 300.4, and 311 on any 
inpatient or outpatient claim during the study period. We also created a variable indicating 
new diagnosis of depression post-TBI for those without a depression diagnosis pre-TBI.
Data Analysis
Distributions of demographic and clinical variables in the study population were assessed 
overall and stratified by receipt of at least one psychotropic medication at any time during 
the study period. Average monthly prevalence of psychotropic use was calculated by 
category for the twelve months prior to and following TBI hospitalization. Antidepressants 
comprise the majority of psychotropic use; therefore we also calculated the average monthly 
prevalence of use of the most common antidepressants: selective serotonin re-uptake 
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tri-cyclic 
antidepressants (TCAs). The ‘other’ antidepressants included mirtazapine, bupropion, 
trazadone, and monoamine oxidase inhibitors. We also calculated average prevalence of use 
for the twenty most prevalent individual psychotropic medications during the pre- and post-
TBI periods. Finally, we created an indicator variable for use of more than one psychotropic 
medication class at one time.
To test time trends in monthly prevalence of psychotropic use over the study period, we used 
linear regression, evaluating trends prior to and following the TBI hospitalization separately. 
We also evaluated trends over the entire study period, excluding the first two months 
following injury because of incomplete reporting of medication use during hospitalization 
and subsequent skilled nursing facility stay. These models were adjusted only for time, and 
informed adjustment of generalized estimating equation models. To test whether TBI 
hospitalization impacted psychotropic use, we used generalized estimating equations with a 
logistic model, accounting for repeated observations and time. As before, we excluded the 
first two months following injury.
We examined whether individuals newly diagnosed with anxiety or PTSD following TBI 
used the same amount of psychotropic medication compared to individuals without TBI. 
However, Medicare beneficiaries hospitalized with TBI differ from other Medicare 
beneficiaries in that they are older with a greater burden of comorbid illness, complicating 
efforts to identify a suitable comparison group.24 Our prior study examining post-TBI 
treatment of depression addressed this issue by using the pre-TBI period as the control.25 We 
used similar methodology to compare receipt of treatment for anxiety and PTSD during the 
pre- and post-TBI periods.
To focus on new use of psychotropic medications associated with diagnosis of anxiety or 
PTSD, we excluded beneficiaries with any use of medications used to treat anxiety or PTSD 
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(depending on the model) during the six months prior to diagnosis. To accurately report use 
of psychotropic medications associated with diagnosis of anxiety or PTSD at the monthly 
level, we created time-varying indicators for new diagnoses using dates of first ICD-9 CM 
code for anxiety disorder or PTSD during the pre- and post-TBI period. For this analysis, we 
compared receipt of treatment pre- vs post-TBI among beneficiaries with new anxiety or 
PTSD diagnoses. The pre- and post-TBI groups were mutually exclusive, but an individual 
with both anxiety and PTSD could contribute follow-up time to both cohorts. We used 
generalized estimated equations with a logistic model to estimate the odds of psychotropic 
medication receipt pre- vs post-TBI among beneficiaries newly diagnosed with anxiety or 
PTSD. Covariates were selected for our models based on bivariate analysis (chi-square or 
Student's t-test p-value < 0.001), a chi-square p-value <0.05 from type-III analysis, and a 
10% or greater change in the effect measure parameter estimate.
This study was approved by the Institutional Review Board of the University of Maryland, 
Baltimore. All analysis was performed with SAS version 9.4 (SAS Institute, Cary, NC).
Results
There were 60,276 beneficiaries meeting inclusion criteria with twelve months continuous 
Medicare Parts A, B, and D with no Part C coverage before and after TBI hospitalization. Of 
these, 42,608 (71%) used a psychotropic medication at least once during the twenty-four 
month study period (Table 1). Beneficiaries who used any psychotropic medication were 
younger (80.4 (standard deviation (sd) 8.3) years vs. 81.1 (sd 8.3) years, Student's t-test, 
Satterthwaite method df=32,614 p<0.001) and more likely to be female (71% vs. 60%, 
Pearson's Χ2=582.2, p<0.001). They were more likely to have Alzheimer's disease and 
related dementias (24% vs. 19%, Pearson's Χ2=2,548.7, p<0.001) and to have originally 
qualified for Medicare benefits due to disability rather than age (14% vs. 8%, Pearson's 
Χ2=423.6, p<0.001). Among beneficiaries who used psychotropic medications, 27% were 
diagnosed with depression pre-TBI and 34% post-TBI, with 18% receiving first-time 
diagnoses post-TBI. Anxiety was diagnosed among 14% pre-TBI and 17% post-TBI, and 
10% received a first-time diagnosis post-TBI. PTSD was rarely diagnosed both pre- and 
post-TBI (<1%).
Average monthly prevalence of psychotropic medication use during the study period was 
44.8% (Table 2). Prevalence of use of two or more psychotropic medications at the same 
time was 14%. Antidepressants were the most commonly used class of medications, with 
average monthly prevalence of 32.5% and of these, SSRIs were the most common (22.2% 
average monthly prevalence). There was a significant time trend in use of psychotropic 
medications over the entire study period (Student's t-test df =21, p<0.001)(Figure 1), even 
when month three was excluded to account for incomplete reporting of medication use 
during hospitalization and subsequent skilled nursing facility stay. Increased use over the 
study period was observed for all psychotropics except TCAs (significant decrease in use, 
Student's t-test df =21, p<0.001) and miscellaneous psychotropics (Student's t-test df =21, 
p=0.12).
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The SSRIs sertraline and escitalopram were the most commonly used psychotropic 
medications before and after TBI (Figure 2). Quetiapine was the most commonly used 
antipsychotic both pre- and post-TBI. Prevalence of use of the anti-seizure agent 
levetiracetam was low pre-TBI but increased five-fold post-TBI.
Accounting for repeated observations and time, odds of using any psychotropic medication 
were increased post-TBI (odds ratio (OR) 1.05; 95% confidence interval (CI) 1.03, 1.06, 
Wald Χ2=36.2, df=1, p<0.001) (Table 2). Overall, antidepressant use decreased slightly post-
TBI, with TCAs showing the largest decrease in use (OR 0.76; 95% CI 0.73, 0.79, Wald 
Χ2=178.5, df=1, p<0.001), even though other antidepressant use increased (OR 1.15; 95% 
CI 1.11, 1.18, Wald Χ2=73.0, df=1, p<0.001 ). The increase in other antidepressant use post-
TBI was driven by mirtazapine (OR 1.31; 95% CI 1.25, 1.37, Wald Χ2=123.3, df=1, 
p<0.001) and trazadone (OR 1.11; 95% CI 1.06, 1.17, Wald Χ2=18.3, df=1, p<0.001)(data 
not shown). Antipsychotic use increased post-TBI (OR 1.15; 95% CI 1.12, 1.19, Wald 
Χ2=103.0, df=1, p<0.001), driven by 15%-20% increases in the atypical antipsychotics 
aripiprazole, quetiapine, olanzapine, and risperidone (data not shown). Mood stabilizer/anti-
seizure use increased significantly post-TBI (OR 1.21; 95% CI 1.19, 1.24, Wald Χ2=250.8, 
df=1, p<0.001). The increase was largest for the anti-seizure drug levetiracetam (OR 4.80; 
95% CI 4.37, 5.28, Wald Χ2=1,066.5, df=1, p<0.001)(data not shown).
There were 3,402 beneficiaries diagnosed with anxiety pre-TBI with no use of indicated 
psychotropic medications during the six months prior to diagnosis and 1,676 beneficiaries 
diagnosed with anxiety for the first time post-TBI and with no use of indicated psychotropic 
medications for at least six-months prior to anxiety diagnosis, for a total of 5,078 
beneficiaries. Our adjusted model contained terms for TBI, age, sex, race, calendar year, 
Alzheimer's disease and related dementias, pre-TBI diagnosis of depression and post-TBI 
diagnosis of depression (these variables were time-varying). Beneficiaries newly diagnosed 
with anxiety post-TBI were less likely to receive indicated pharmacologic treatment (OR 
0.42; 95% CI 0.36, 0.48, Wald Χ2=145.5, df=1, p<0.001)(Table 3).
There were 51 beneficiaries diagnosed with PTSD pre-TBI with no use of indicated 
psychotropic medications during the six months prior to diagnosis and 34 beneficiaries 
diagnosed with PTSD for the first time post-TBI with no use of indicated psychotropic 
medications for at least six months prior to PTSD diagnosis, for a total of 85 beneficiaries. 
Our adjusted model contained terms for TBI and original reason for Medicare entitlement 
(age, disability, end-stage renal disease). Beneficiaries newly diagnosed with PTSD post-
TBI were less likely to receive indicated pharmacologic treatment (OR 0.39; 95% CI 0.18, 
0.84, Wald Χ2=5.8, df=1, p=0.02) (Table 3).
Discussion
In this national study of Medicare beneficiaries hospitalized with TBI, almost three-quarters 
used psychotropic medications at least once and monthly prevalence of use increased over 
the 24 month study period. The majority of those using psychotropic medications did not 
receive a diagnosis of depression, anxiety, or PTSD during the study period. After 
accounting for repeated measures and time, hospitalization for TBI resulted in decreases in 
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antidepressant use after discharge while use of mood stabilizers/anti-seizure medications and 
antipsychotics increased. Compared to individuals diagnosed with anxiety or PTSD pre-TBI, 
those diagnosed post-TBI were much less likely to receive indicated pharmacological 
treatment.
Although information on prevalence of psychotropic use is limited, prevalence of 
antidepressant use (33%) in our study was much higher than prior estimates. Kantor et al. 
(2015) assessed antidepressant use among participants ≥18 years in the National Health and 
Nutrition Examination Survey and reported that during 2007-2010, 12% of study 
participants reported using an antidepressant in the past 30 days.26 Depression has been 
identified as a potential risk factor for TBI, hence our sample may have been enriched for 
individuals with greater antidepressant use.27,28 Consistent with this hypothesis, the sample 
population was majority female and had a high prevalence of Alzheimer's, two factors 
associated with depression.29-31 Additionally, there is some evidence of an association 
between SSRIs and increased risk of falls and fractures, suggesting that we may be 
observing a risk factor for TBI, although our study did not examine this question.32,33
The SSRIs sertraline and escitalopram were the most commonly prescribed psychotropic 
medications both pre- and post-TBI, consistent with results of a previous study conducted 
among older adults and with currently used treatments for depression following TBI. 8,11,34 
Odds of TCA use, which can lower the seizure threshold and is associated with increased 
risk of metabolic and anticholinergic side-effects, decreased 24% compared with the pre-
TBI period.8,11 This large decrease suggests prescriber awareness of potential adverse events 
associated with TCA use following TBI that may be leading to either discontinuation or 
switching from TCAs to a different psychotropic medication. There was an overall small but 
significant decrease in antidepressant use not completely attributable to TCAs that supports 
discontinuation following TBI and may reflect caution on the part of providers to continue 
prescribing antidepressants, perhaps due to a desire to decrease polypharmacy or possibly 
knowledge that certain antidepressants are associated with increased fall risk. Use of the 
sedating antidepressants trazadone and mirtazapine increased moderately (15% increase in 
odds of use) post-TBI, likely resulting from treatment of sleep disturbances, common 
following TBI. 8 Finally, odds of use of atypical antipsychotics, among which quetiapine is 
most commonly used, increased by a moderate 15% post-TBI. Quetiapine, and to a lesser 
extent risperidone, is often used for the treatment of insomnia, agitation, and aggression 
following TBI. 8
Individuals newly diagnosed with anxiety and PTSD post-TBI were much less likely to 
receive indicated medications for treatment of these disorders compared to similar 
individuals diagnosed with anxiety and PTSD before TBI. This finding is consistent with our 
previous results on treatment of depression following TBI and provides evidence that among 
older adults, there is a disparity in receipt of treatment for the three most common 
neuropsychiatric disorders following TBI.25 Older adults are more likely to initially consult 
with a primary care provider for psychological problems and receive a psychiatric diagnosis 
from a non-specialty setting.32 However, these providers may not feel comfortable 
prescribing psychotropic medications following TBI in the absence of evidence based 
recommendations.11,12,35 The disparity may also result from the perception that a 
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psychological reaction to trauma is expected and will resolve on its own without treatment. 
Cognitive impairment, common following TBI, may also impede filling prescribed 
medications or following up with providers for refills.36
Limitations of this study include lack of a comparison group of Medicare beneficiaries who 
were not hospitalized with TBI. Although we used the pre-TBI period for comparison, it is 
likely that psychotropic medication use in this population is different from and possibly 
higher than that of other Medicare beneficiaries. Information on TBI severity is missing 
from administrative claims; however, neuropsychiatric disturbances occur regardless of TBI 
severity and current pharmacologic treatments do not account for severity of injury.8,11 
Furthermore, this study includes only beneficiaries hospitalized with TBI. These individuals 
may have been more severely injured or more susceptible to complications compared to 
those who were treated and released in the emergency department. If these factors were also 
associated with psychotropic medication use, bias could result. Future studies should focus 
on different populations to help determine the extent of this potential bias. Additionaly, 
while we assessed filled prescriptions, we don't have information on medications prescribed 
but not filled or adherence to filled prescriptions. Therefore, observed differences in 
psychotropic medication use pre-post TBI may be due to lack of prescribing or lack of 
follow-up on the part of the patient. Finally, we don't know the indications for which 
beneficiaries were receiving psychotropic medications.
Nonetheless, this is the largest study of psychotropic medication use among individuals with 
TBI and it provides critical information on current usage patterns before and after TBI 
hospitalization. Comparative safety and effectiveness analyses could initially target the 
medications we identified as most often used. Furthermore, this study highlights a disparity 
in receipt of pharmacological treatment for newly diagnosed anxiety and PTSD following 
TBI. Future studies should focus on elucidated underlying reasons for the observed disparity 
and whether younger adults are equally affected. More research is also needed to determine 
the efficacy of psychotropic medications following TBI, their specific side-effects and drug-
drug interactions and the role of non-pharmacological strategies. Physicians should be 
cognizant of these factors and be extremely cautious in prescribing psychotropics in elderly 
individuals with TBI who are often being treated pharmacologically for other medical 
conditions.
In conclusion, Medicare beneficiaries hospitalized with TBI have a high prevalence of 
psychotropic medication use both before and after TBI yet are less likely to receive indicated 
pharmacological treatment for newly diagnosed anxiety and PTSD following TBI.
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Monthly Prevalence of Psychotropic Medication Use among Medicare Beneficiaries 
Hospitalized with Traumatic Brain Injury 2006-2010 During Twelve Months Pre- and Post-
TBI, n= 60,276
TBI – traumatic brain injury; SSRI – selective serotonin reuptake inhibitor; SNRI – 
serotonin norepinephrine reuptake inhibitor; TCA – tricyclic antidepressant; AP – 
antipsychotic; MS/AS – mood stabilizer/anti-seizure; PT – any psychotropic; MPT – 
miscellaneous psychotropic; *Dip post-TBI is caused by incomplete capture of drug claims 
data during hospitalization and subsequent skilled nursing facility stay
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Average Monthly Prevalence of the Twenty Most Commonly Used Psychotropic 
Medications among Medicare Beneficiaries During the Twelve Months Pre- and Post-
Hospitalization with Traumatic Brain Injury 2006-2010, n= 60,276
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Table 1
Baseline Characteristics of Medicare Beneficiaries Hospitalized with Traumatic Brain Injury 2006-2010 by 
Receipt of Psychotropic Medications at any Time During the Study Period, n= 60,276
Total Sample N= 60,276 Psychotropic Use, N= 
42,608
No Psychotropic Use, N= 
17,668 p-value
1
Age, mean (standard deviation) 81.0 (8.3) 80.4 (8.4) 81.1 (8.3) <0.001
Female sex, n(%) 40,735 (68) 30,057 (71) 10,678 (60) <0.001
Race/Ethnicity
2 <0.001
    White 53,030 (86) 37,081 (87) 14,949 (85)
    Black 3,489 (6) 2,346 (6) 1,143 (6)
    Other 4,757 (8) 3,181 (7) 1,576 (9)
Comorbid conditions, n(%)
    Alzheimer's disease 13,439 (22) 10,103 (24) 3,336 (19) <0.001
    Chronic kidney disease 10,465 (17) 7,615 (18) 2,850 (16) <0.001
    COPD
3 6,190 (10) 4,562 (11) 1,628 (9) <0.001
    Diabetes 4,813 (8) 3,518 (8) 1,295 (7) <0.001
    Heart failure 8,582 (14) 6,220 (15) 2,362 (13) <0.001
    Ischemic heart disease 6,135 (10) 4,143 (10) 1,992 (11) <0.001
    Neurologic disease 7,341 (12) 5,661 (13) 1,680 (10) <0.001
    Rheumatoid arthritis / osteoarthritis 6,792 (11) 4,529 (11) 2,263 (13) <0.001
    Stroke / transient ischemic attack 13,664 (23) 9,804 (23) 3,860 (22) 0.002
Psychological disorders, n (%)
    Depression pre-TBI 12,027 (20) 11,573 (27) 454 (3) <0.001
    Depression post-TBI 15,429 (26) 14,692 (34) 737 (4) <0.001
    New depression post-TBI 8,396 (14) 7,798 (18) 598 (3) <0.001
    Anxiety pre-TBI 6,902 (11) 6,294 (14) 608 (3) <0.001
    Anxiety post-TBI 8,113 (13) 7,341 (17) 772 (4) <0.001
    New Anxiety post-TBI 5,017 (8) 4,438 (10) 579 (3) <0.001
    PTSD
4
 pre-TBI
95 (<1) 88 (<1) 7 (<1) <0.001
    PTSD
4
 post-TBI
136 (<1) 124 (<1) 12 (<1) <0.001
    New PTSD
4
 post-TBI





    Age 52,823 (88) 36,584 (86) 16,239 (92)
    Disability 7,322 (12) 5,924 (14) 1,398 (8)
    ESRD
6
 +/− disability
131 (<1) 100 (<1) 31 (<1)
1




Chronic obstructive pulmonary disease
4
Post-traumatic stress disorder
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5
Original reason for Medicare entitlement
6
End stage renal disease
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Table 2
Average Monthly Prevalence of Psychotropic Medication Use and Odds Ratios Comparing Use Post- to Pre-
TBI
1
, Adjusted for Time, among Medicare Beneficiaries Hospitalized with TBI 2006-2010 During Twelve 
Months Pre- and Post-TBI, n= 60,276
Pre-TBI Post-TBI Entire Period Odds Ratio (95% Confidence Interval) Wald X2, p-value
2
Any Psychotropic Medication 41.8% 47.8% 44.8% 1.05 (1.03, 1.06) 36.2, <0.001
Any Antidepressant 30.9% 34.1% 32.5% 0.96 (0.95, 0.98) 25.7, <0.001
    SSRI
3 21.0% 23.4% 22.2% 0.96 (0.94, 0.97) 25.5, <0.001
    SNRI
4 4.2% 4.6% 4.4% 0.89 (0.86, 0.92) 48.6, <0.001
    TCA
5 3.8% 2.8% 3.3% 0.76 (0.73, 0.79) 178.5, <0.001
    Other Antidepressants 6.1% 8.2% 7.1% 1.15 (1.11, 1.18) 73.0, <0.001
Antipsychotics 7.1% 9.9% 8.5% 1.15 (1.12, 1.19) 103.0, <0.001
Mood Stabilizers/Anti-Seizure 10.3% 14.0% 12.2% 1.21 (1.19, 1.24) 250.8, <0.001
Other Anxiolytics 0.9% 0.9% 0.9% 1.03 (0.94, 1.11) 0.34, 0.56






Selective serotonin reuptake inhibitors
4
Serotonin norepinephrine reuptake inhibitors
5
Tricyclic antidepressants
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Table 3
Among Patients Newly Diagnosed with Anxiety or Post-Traumatic Stress Disorder, Odds of Receiving 
Indicated Pharmacologic Treatment Post-TBI Compared to Pre-TBI: Medicare Beneficiaries Hospitalized with 
TBI 2006-2010
Odds Ratio (95% Confidence Interval) Wald X2, p-value
Anxiety, n=5,078
    Unadjusted 0.52 (0.46, 0.58) 126.9, <0.001
    Adjusted
1 0.42 (0.36, 0.48) 145.5, <0.001
Post-traumatic Stress Disorder, n=85
    Unadjusted 0.32 (0.15, 0.67) 9.25, 0.002
    Adjusted
2 0.39 (0.18, 0.84) 5.8, 0.02
1
post-TBI, age, sex, race, calendar year, Alzheimer's disease and related dementias, depression pre-TBI, depression post-TBI
2
post-TBI, original reason for Medicare entitlement (age, disability, end-stage renal disease)
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